Cumulative inflammatory burden is independently associated with increased arterial stiffness in patients with psoriatic arthritis: a prospective study

Jiayun Shen, Qing Shang, Edmund K Li, Ying-Ying Leung, Emily W Kun, Lai-Wa Kwok, Martin Li, Tena K Li, Tracy Y Zhu, Cheuk-Man Yu, Lai-Shan Tam, Jiayun Shen, Qing Shang, Edmund K Li, Ying-Ying Leung, Emily W Kun, Lai-Wa Kwok, Martin Li, Tena K Li, Tracy Y Zhu, Cheuk-Man Yu, Lai-Shan Tam

Abstract

Introduction: The aim of this study was to examine whether the cumulative inflammatory burden is associated with an increase in arterial stiffness in a prospective cohort of psoriatic arthritis (PsA) patients.

Methods: In total, 72 PsA patients were followed for a median of 6.5 years. Cumulative inflammatory burden was represented by the cumulative averages of repeated measures of erythrocyte sedimentation rate (ca-ESR) and C-reactive protein (ca-CRP). Brachial-ankle pulse wave velocity (PWV) was measured at the last visit. We also included 47 healthy controls for PWV assessment.

Results: PWV was significantly higher in PsA patients compared with healthy controls after adjustment for age, gender and body weight (1466±29 cm/s versus 1323±38 cm/s, P=0.008). PsA patients were divided into two groups based on whether their PWV value is ≥1450 cm/s (High PWV group, N=38) or <1450 cm/s (Low PWV group, N=34). The High PWV group had a significantly higher ca-ESR (29 (19 to 44) versus 18 (10 to 32) mm/1st hour, P=0.005) and ca-CRP (0.7 (0.3 to 1.4) versus 0.4 (0.2 to 0.7) mg/dl, P=0.029). Using regression analysis, high ca-ESR (defined as ≥75th percentile: 37 mm/1st hour) was associated with a higher likelihood of being in the High PWV group (odds ratio (OR): 9.455 (1.939 to 46.093), P=0.005, adjusted for baseline clinical and cardiovascular risk factors; and 9.111 (1.875 to 44.275), P=0.006, adjusted for last visit parameters).

Conclusions: Cumulative inflammatory burden, as reflected by ca-ESR, was associated with increased arterial stiffness in PsA patients even after adjustment for cardiovascular risk factors, emphasizing the important role of chronic inflammation in accelerating the development of cardiovascular risks in PsA patients.

Figures

Figure 1
Figure 1
Pulse wave velocity (PWV) in control subjects and patients with psoriatic arthritis (PsA). (A) Unadjusted mean in control subjects (n = 47) and all PsA patients (n = 72). (B) Mean adjusted by age, gender and body weight in control subjects and all PsA patients. (C) Mean adjusted by age, gender and body weight in control subjects and PsA patients without hypertension, diabetes or hyperlipidemia (n = 20).
Figure 2
Figure 2
Cumulative inflammatory burden and pulse wave velocity (PWV). Cumulative average of erythrocyte sedimentation rate (ca-ESR) and C-reactive protein (CRP) in the low PWV group (PWV <1,450 cm/s, n = 34) and the high-PWV group (PWV ≥1,450 cm/s, n = 38).

References

    1. Tam LS, Shang Q, Li EK, Tomlinson B, Chu TT, Li M, et al. Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum. 2008;59:1322–31. doi: 10.1002/art.24014.
    1. Zhu TY, Li EK, Tam LS. Cardiovascular risk in patients with psoriatic arthritis. Int J Rheumatol. 2012;2012:714321.
    1. Han C, Robinson DW, Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006;33:2167–72.
    1. Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum. 1998;41:1103–10. doi: 10.1002/1529-0131(199806)41:6<1103::AID-ART18>;2-N.
    1. Tam LS, Tomlinson B, Chu TT, Li M, Leung YY, Kwok LW, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls–the role of inflammation. Rheumatology (Oxford) 2008;47:718–23. doi: 10.1093/rheumatology/ken090.
    1. Tam LS, Kitas GD, Gonzalez-Gay MA. Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis? Rheumatology (Oxford) 2014;53:1108–19. doi: 10.1093/rheumatology/ket454.
    1. Park S, Lakatta EG. Role of inflammation in the pathogenesis of arterial stiffness. Yonsei Med J. 2012;53:258–61. doi: 10.3349/ymj.2012.53.2.258.
    1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–95. doi: 10.1056/NEJMra043430.
    1. Eder L, Zisman D, Barzilai M, Laor A, Rahat M, Rozenbaum M, et al. Subclinical atherosclerosis in psoriatic arthritis: a case–control study. J Rheumatol. 2008;35:877–82.
    1. Eder L, Thavaneswaran A, Chandran V, Cook R, Gladman DD. Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis. Ann Rheum Dis. 2014. doi: 10.1136/annrheumdis-2014-205267. [Epub ahead of print]
    1. Giles JT, Post WS, Blumenthal RS, Polak J, Petri M, Gelber AC, et al. Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritis. Arthritis Rheum. 2011;63:3216–25. doi: 10.1002/art.30542.
    1. Gonzalez-Gay MA, Gonzalez-Juanatey C, Pineiro A, Garcia-Porrua C, Testa A, Llorca J. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol. 2005;32:1219–23.
    1. Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, Pineiro A, Garcia-Porrua C, Miranda-Filloy JA, et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum. 2007;57:125–32. doi: 10.1002/art.22482.
    1. Cavalcante JL, Lima JA, Redheuil A, Al-Mallah MH. Aortic stiffness: current understanding and future directions. J Am Coll Cardiol. 2011;57:1511–22. doi: 10.1016/j.jacc.2010.12.017.
    1. Vlachopoulos C, Aznaouridis K, Terentes-Printzios D, Ioakeimidis N, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with brachial-ankle elasticity index: a systematic review and meta-analysis. Hypertension. 2012;60:556–62. doi: 10.1161/HYPERTENSIONAHA.112.194779.
    1. Wu L, Wang Y, Zheng L, Li J, Hu D, Xu Y, et al. Distribution of brachial-ankle pulse wave velocity values and optimal cut-off in distinguishing subjects with clinical condition in Chinese population. Int Angiol. 2012;31:252–9.
    1. Costa L, Caso F, D’Elia L, Atteno M, Peluso R, Del Puente A, et al. Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol. 2012;31:711–5. doi: 10.1007/s10067-011-1892-1.
    1. Soy M, Yildiz M, Sevki Uyanik M, Karaka N, Gufer G, Piskin S. Susceptibility to atherosclerosis in patients with psoriasis and psoriatic arthritis as determined by carotid-femoral (aortic) pulse-wave velocity measurement. Rev Esp Cardiol (Engl Ed) 2009;62:96–9. doi: 10.1016/S0300-8932(09)70027-2.
    1. Crilly MA, Kumar V, Clark HJ, Scott NW, Macdonald AG, Williams DJ. Arterial stiffness and cumulative inflammatory burden in rheumatoid arthritis: a dose–response relationship independent of established cardiovascular risk factors. Rheumatology (Oxford) 2009;48:1606–12. doi: 10.1093/rheumatology/kep305.
    1. Maki-Petaja KM, Hall FC, Booth AD, Wallace SM, Yasmin, Bearcroft PW, et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation. 2006;114:1185–92. doi: 10.1161/CIRCULATIONAHA.105.601641.
    1. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–73. doi: 10.1002/art.21972.
    1. Wong PC, Leung YY, Li EK, Tam LS. Measuring disease activity in psoriatic arthritis. Int J Rheumatol. 2012;2012:839425.
    1. Fredriksson T, Pettersson U. Severe psoriasis–oral therapy with a new retinoid. Dermatologica. 1978;157:238–44. doi: 10.1159/000250839.
    1. Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res (Hoboken). 2011;63:S64–85
    1. Shang Q, Tam LS, Li EK, Yip GW, Yu CM. Increased arterial stiffness correlated with disease activity in systemic lupus erythematosus. Lupus. 2008;17:1096–102. doi: 10.1177/0961203308092160.
    1. Tam LS, Shang Q, Li EK, Wong S, Li RJ, Lee KL, et al. Serum soluble receptor for advanced glycation end products levels and aortic augmentation index in early rheumatoid arthritis–a prospective study. Semin Arthritis Rheum. 2013;42:333–45. doi: 10.1016/j.semarthrit.2012.07.002.
    1. Dessein PH, Joffe BI, Veller MG, Stevens BA, Tobias M, Reddi K, et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol. 2005;32:435–42.
    1. Shang Q, Tam LS, Sanderson JE, Sun JP, Li EK, Yu CM. Increase in ventricular-arterial stiffness in patients with psoriatic arthritis. Rheumatology (Oxford) 2012;51:2215–23. doi: 10.1093/rheumatology/kes213.
    1. Ahlehoff O, Gislason GH, Charlot M, Jorgensen CH, Lindhardsen J, Olesen JB, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011;270:147–57. doi: 10.1111/j.1365-2796.2010.02310.x.
    1. Ali Y, Tom BD, Schentag CT, Farewell VT, Gladman DD. Improved survival in psoriatic arthritis with calendar time. Arthritis Rheum. 2007;56:2708–14. doi: 10.1002/art.22800.
    1. Mok CC, Kwok CL, Ho LY, Chan PT, Yip SF. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong. China Arthritis Rheum. 2011;63:1182–9. doi: 10.1002/art.30277.
    1. Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I Causes and risk of death. Arthritis Rheum. 1997;40:1868–72. doi: 10.1002/art.1780401021.
    1. Buckley C, Cavill C, Taylor G, Kay H, Waldron N, Korendowych E, et al. Mortality in psoriatic arthritis - a single-center study from the UK. J Rheumatol. 2010;37:2141–4. doi: 10.3899/jrheum.100034.
    1. Shbeeb M, Uramoto KM, Gibson LE, O’Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982–1991. J Rheumatol. 2000;27:1247–50.
    1. Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis. 2009;68:1131–5. doi: 10.1136/ard.2008.094839.
    1. Westerweel PE, Verhaar MC. Endothelial progenitor cell dysfunction in rheumatic disease. Nat Rev Rheumatol. 2009;5:332–40. doi: 10.1038/nrrheum.2009.81.
    1. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25:932–43. doi: 10.1161/01.ATV.0000160548.78317.29.
    1. Bailey AJ. Molecular mechanisms of ageing in connective tissues. Mech Ageing Dev. 2001;122:735–55. doi: 10.1016/S0047-6374(01)00225-1.
    1. Lee AT, Cerami A. Role of glycation in aging. Ann NY Acad Sci. 1992;663:63–70. doi: 10.1111/j.1749-6632.1992.tb38649.x.
    1. Throckmorton DC, Brogden AP, Min B, Rasmussen H, Kashgarian M. PDGF and TGF-beta mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int. 1995;48:111–7. doi: 10.1038/ki.1995.274.
    1. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem. 1994;269:9889–97.
    1. Mease PJ. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis. 2002;61:298–304. doi: 10.1136/ard.61.4.298.
    1. Gokce N, Vita JA. Clinical manifestations of endothelial dysfunction. In: Loscalzo J, Schafer AI, editors. Thrombosis and Hemorrhage. 3. Philadelphia, PA: Lippincott, Williams and Wilkins; 2002. pp. 685–706.
    1. Angel K, Provan SA, Fagerhol MK, Mowinckel P, Kvien TK, Atar D. Effect of 1-year anti-TNF-alpha therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. Am J Hypertens. 2012;25:644–50. doi: 10.1038/ajh.2012.12.
    1. Sugawara J, Hayashi K, Yokoi T, Cortez-Cooper MY, DeVan AE, Anton MA, et al. Brachial-ankle pulse wave velocity: an index of central arterial stiffness? J Hum Hypertens. 2005;19:401–6. doi: 10.1038/sj.jhh.1001838.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren